Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDT
MDT logo

MDT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
85.360
Open
85.250
VWAP
83.77
Vol
4.10M
Mkt Cap
109.13B
Low
82.905
Amount
343.55M
EV/EBITDA(TTM)
12.86
Total Shares
1.28B
EV
129.03B
EV/OCF(TTM)
17.71
P/S(TTM)
--
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
Show More

Events Timeline

No data

No data

News

PRnewswire
8.5
04-20PRnewswire
PinnedMedtronic Acquires CathWorks, Redefining Cardiovascular Care
  • Acquisition Scale: Medtronic's acquisition of CathWorks for $585 million not only solidifies its leadership in the cardiovascular sector but also enhances its product portfolio with the innovative FFRangio system, expected to boost the company's competitiveness in global markets.
  • Technological Innovation: The CathWorks FFRangio system employs artificial intelligence and advanced computational science to provide non-invasive physiological assessments, significantly improving the accuracy and efficiency of cardiac disease diagnosis, which is anticipated to enhance patient treatment outcomes and reduce healthcare resource utilization.
  • Clinical Trial Results: At the 2026 American College of Cardiology conference, CathWorks presented results from the ALL-RISE randomized control trial, demonstrating that the system is non-inferior to traditional methods in terms of major adverse cardiac events (MACE), further validating its clinical application effectiveness.
  • Strategic Implications: This acquisition marks a significant advancement in Medtronic's digital transformation efforts, expected to expand global access to FFRangio technology, thereby enhancing physicians' diagnostic capabilities and providing higher quality medical services to patients.
NASDAQ.COM
9.5
04-19NASDAQ.COM
Intuitive Surgical Reports Continued Growth Amid Rising Competition
  • Revenue and Earnings Growth: Intuitive Surgical reported $10.1 billion in revenue for 2025, marking a 21% increase, with earnings per share (EPS) of $7.87, up 22.5%, reflecting strong performance and sustained market demand in the medical device sector.
  • Surgical System Usage: The da Vinci robotic platform has performed over 20 million surgeries, with the da Vinci Xi system alone used in over 3 million procedures last year, solidifying its leadership in the global multiport robotic surgery market.
  • Increased Market Competition: Despite holding a dominant position in robotic surgery, the entry of competitors like Johnson & Johnson and Medtronic, along with Restore Robotics' alternative tools, may pressure its market share, although revenue and procedure volumes continue to rise.
  • Technological Innovation and Investment: Intuitive Surgical invested $1.3 billion in R&D last year, and the rollout of the da Vinci 5 system, featuring force feedback technology, is expected to be a major growth catalyst for 2026, further strengthening its market position.
Fool
8.5
04-19Fool
Intuitive Surgical: Leader in Robotic Surgery Market
  • Market Dominance: Intuitive Surgical's da Vinci Xi system is the most widely used multiport robotic surgery system globally, utilized in over 3 million surgeries last year; despite a more than 17% drop in stock price this year, its market share remains robust.
  • Training Barrier: Most surgeons trained on the da Vinci platform during residency face significant retraining to switch to competitors' systems, making hospitals reluctant to disrupt established workflows in high-stakes surgery, thereby solidifying Intuitive's market position.
  • Economic Cycle Advantage: With over 12,100 systems installed globally, 81% of Intuitive's revenue comes from recurring sales of instruments, accessories, and services, making it unlikely for hospitals to replace existing da Vinci systems even if they purchase a competitor's robot due to substantial capital already invested.
  • Innovation Drive: The company invested $1.3 billion in R&D last year, with the rollout of the da Vinci 5 expected to be a major catalyst for 2026; its force feedback technology can reduce applied force by up to 43%, improving surgical outcomes and enhancing competitive strength.
Newsfilter
7.5
04-16Newsfilter
Structural Shift in U.S. Heart Care Market
  • Market Growth Potential: The U.S. cardiovascular devices market is projected to grow from $22.08 billion in 2025 to $41.29 billion by 2032, reflecting a nearly 11.3% annual growth rate, indicating significant demand driven by an aging population.
  • AI Tool Adoption: Currently, 75% of U.S. health systems are rolling out AI-powered clinical tools, particularly in cardiac imaging and documentation, which will create asymmetric growth opportunities for companies in this sector.
  • New Partnership: VentriPoint Diagnostics has secured a new partnership with the Montecristo Group to deploy its AI cardiac imaging platform across Costa Rica, which is expected to enhance the efficiency and accuracy of cardiac disease screening in the region, further expanding market share.
  • Technological Advantage: VentriPoint's VMS+™ system converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRIs at a significantly lower cost, which is anticipated to drive the widespread adoption of cardiac diagnostics.
PRnewswire
9.5
04-13PRnewswire
Medtronic to Report Q4 and FY2026 Results on June 3
  • Earnings Announcement: Medtronic has announced it will report its fourth quarter and full fiscal year 2026 financial results on June 3, 2026, following the fiscal year ending on April 24, 2026, providing investors with insights into its financial health and performance.
  • Global Leadership: As a leader in healthcare technology, Medtronic is committed to addressing significant health challenges, employing over 95,000 people across more than 150 countries, showcasing its extensive influence in the healthcare sector.
  • Technology and Treatment Range: The company offers technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, and insulin pumps, demonstrating its robust capabilities in medical innovation and diverse product offerings.
  • Mission and Vision: Medtronic's mission to alleviate pain, restore health, and extend life underscores its commitment to improving global health outcomes, driving people-centered care, and achieving better medical results.
Newsfilter
9.5
04-13Newsfilter
Medtronic to Report Q4 and FY2026 Results on June 3
  • Earnings Announcement Schedule: Medtronic is set to report its Q4 and full fiscal year 2026 financial results on June 3, 2026, with the fiscal year ending on April 24, 2026, reflecting the company's commitment to transparency.
  • Information Release Timing: Financial information will be released at 5:45 a.m. Central Time, followed by a video webcast, indicating the company's intention to enhance investor confidence through timely communication.
  • Commitment to Innovation: Medtronic is dedicated to addressing global health challenges through its innovative technologies and therapies that treat 70 health conditions, underscoring its leadership in the healthcare technology sector.
  • Global Team Scale: With over 95,000 employees across more than 150 countries, Medtronic demonstrates its extensive influence and resource integration capabilities in the global healthcare market.
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
Wall Street analysts forecast MDT stock price to rise
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
102.00
Averages
111.76
High
120.00
Current: 0.000
sliders
Low
102.00
Averages
111.76
High
120.00
Truist
Richard Newitter
Hold
downgrade
$103 -> $95
AI Analysis
2026-04-15
Reason
Truist
Richard Newitter
Price Target
$103 -> $95
AI Analysis
2026-04-15
downgrade
Hold
Reason
Truist analyst Richard Newitter lowered the firm's price target on Medtronic to $95 from $103 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds that the stock's discount could narrow given that we are now one quarter closer to potentially meaningful revenue accelerants, though the company will have to demonstrate faster revenue and EPS growth prospects for sustainably higher multiples.
Mizuho
Outperform
to
Outperform
downgrade
$125 -> $120
2026-04-13
Reason
Mizuho
Price Target
$125 -> $120
2026-04-13
downgrade
Outperform
to
Outperform
Reason
Mizuho lowered the firm's price target on Medtronic to $120 from $125 and keeps an Outperform rating on the shares. The firm adjusted estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MDT
Unlock Now

Valuation Metrics

The current forward P/E ratio for Medtronic PLC (MDT.N) is 14.12, compared to its 5-year average forward P/E of 16.89. For a more detailed relative valuation and DCF analysis to assess Medtronic PLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
16.89
Current PE
14.12
Overvalued PE
19.27
Undervalued PE
14.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
14.35
Current EV/EBITDA
12.71
Overvalued EV/EBITDA
16.18
Undervalued EV/EBITDA
12.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.68
Current PS
2.89
Overvalued PS
4.36
Undervalued PS
3.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding MDT

T
Todd Asset Management LLC
Holding
MDT
+99.00%
3M Return
S
Schroder Investment Management Limited
Holding
MDT
+58.82%
3M Return
H
HANSAINVEST Hanseatische Investment-GmbH
Holding
MDT
+26.18%
3M Return
H
Hardman Johnston Global Advisors LLC
Holding
MDT
+19.89%
3M Return
T
Thornburg Investment Management, Inc.
Holding
MDT
+19.43%
3M Return
M
MAPFRE Asset Management
Holding
MDT
+15.97%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Medtronic PLC (MDT) stock price today?

The current price of MDT is 83.04 USD — it has decreased -2.31

What is Medtronic PLC (MDT)'s business?

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

What is the price predicton of MDT Stock?

Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is111.76 USD with a low forecast of 102.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Medtronic PLC (MDT)'s revenue for the last quarter?

Medtronic PLC revenue for the last quarter amounts to 9.02B USD, increased 8.74

What is Medtronic PLC (MDT)'s earnings per share (EPS) for the last quarter?

Medtronic PLC. EPS for the last quarter amounts to 0.89 USD, decreased -11.88

How many employees does Medtronic PLC (MDT). have?

Medtronic PLC (MDT) has 95000 emplpoyees as of April 21 2026.

What is Medtronic PLC (MDT) market cap?

Today MDT has the market capitalization of 109.13B USD.